A phase 2 trial found that combining Camrelizumab and Apatinib showed promising results in patients with refractory chordoma, a rare and aggressive spine cancer. The study included 33 patients.
The combination achieved an objective response rate of 24.2% by RECIST 1.1 and 48.5% by Choi criteria, with a disease control rate of 90.9%. Median progression-free survival reached 28.4 months, while median overall survival had not yet been reached. Patients with CDKN2A alterations had poorer responses and shorter progression-free survival.
Grade 3 or 4 treatment-related side effects occurred in 60.6% of patients, most commonly elevated AST and ALT levels. No treatment-related deaths were reported. Researchers said larger multicenter phase 3 studies are needed to confirm the findings.